Can a natural supplement soothe diabetic nerve pain?
NCT ID NCT07377409
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests whether a dietary supplement called Cronilief (palmitoylethanolamide) can reduce nerve pain in people with diabetes when added to their usual treatment. Seventy adults with moderate nerve pain will take either the supplement or a placebo for 8 weeks. The goal is to see if it improves pain and sleep quality.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- Cronilief (palmitoylethanolamide phospholipids)
- What this could lead to
- If it works, this could offer a natural supplement option to help manage nerve pain in people with diabetes.
- What could go wrong
- This is a small, early-stage trial with only 70 people. The supplement may not work better than placebo, and results may not apply to everyone with diabetic nerve pain.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 70 people
The number the study aims to enrol. It can still change while the study runs.
- Expected to start
-
Sep 2026
An estimate. Start dates often move.
- Expected to finish
-
Jan 2027
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 to 65 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Satisfactory metabolic compensation; * Presence of moderate symptoms of painful diabetic neuropathy as assessed by the LANSS questionnaire (score ≥12); * Taking antidiabetic drugs except insulin; * Subjects willing and able to comply with scheduled study visits, the treatment plan, and all procedures outlined in the study. Exclusion Criteria: * Previous intolerance to a component of the nutraceuticals tested; * Individuals with type I diabetes; * Uncontrolled diabetes, severe cardiovascular and cerebrovascular diseases; * Severe neuropathic symptoms as indicated by the LANSS score; * Individuals undergoing insulin treatment; * Peripheral neuropathy due to diseases other than diabetes mellitus; * History of malignant neoplasm in the 5 years prior to enrolment in the study; * Serious neurological, psychological or psychiatric disorders; * Clinical signs or history of significant impairment of hepatic or renal function, peptic ulcer or coagulation disorders; * Any clinically relevant or unstable disease (e.g., active malignancies, immune system disorders) whose sequelae or treatments could contraindicate participation in the study or interfere with the study's evaluation parameters, in the investigator's judgement; Any disease that could significantly affect the study's outcome, including, but not limited to, chronic medical conditions, psychological disorders, or substance abuse; * Alcohol or drug abuse; * Women of childbearing age who do not use established contraceptive methods; * Pregnancy and breastfeeding.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Diabetic neuropathies, painful are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The official record
The full official record for this study. This one lists no contact details, but it is the first place any would appear.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
More trials for these conditions
Other studies related to the condition(s) this trial covers.